1. National Institutes of Health Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention: A Pocket Guide for Physicians and Nurses. Bethesda, MD: National Institutes of Health, 2002.

2. Louis R, Lau LCK, Bron AO et al. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000;161:9-16.

3. Bjermer L. History and future perspectives of treating asthma as a systemic and small airways disease. Respir Med 2001;95:703-719.

4. Diamant Z, Sampson AP. Anti-inflammatory mechanisms of leukotriene modulators. Clin Exp Allergy 1999;29:1449-1453.

5. Bisgaard H. Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma. Allergy 2001;56(suppl 66):7-11.

6. Holgate ST, Peters-Golden M. Introduction: The anti-inflammatory role of cysteinyl leukotriene receptor antagonists in asthma. J Allergy Clin Immunol 2003;111(1 suppl):S1-S4.

7. Holgate ST, Peters-Golden M, Panettieir RA et al. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol 2003;111(1 suppl):S18-S36.

8. Henderson WR Jr, Tang L, Chu S-J. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med 2002;165:108-116.

9. Peters-Golden M, Sampson AP. Cysteinyl leukotriene interactions with other mediators and with glucocorticosteroids during airway inflammation. J Allergy Clin Immunol 2003;111(1 suppl): S37-S42; discussion S43-S48.

10. Varner AE, Lemanske RF Jr. The early and late asthmatic response to allergen. In: Busse WW, Holgate ST, eds. Asthma and Rhinitis. Oxford, UK: Blackwell Science, 2000:1172-1185.

11. Barnes PJ. Mechanism of action of glucocorticoids in asthma. Am J Respir Crit Care Med 1996;154:S21-S27.

12. Robinson D, Hamid Q, Ying S et al. Prenisolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5, and interferon-ã cytokine gene expression. Am Rev Respir Dis 1993;148:401-406.

13. Csoma Z, Kharitonov SA, Balint B et al. Increased leukotrienes in exhaled breath condensate in childhood asthma. Am J Respir Crit Care Rev 2002;166:1345-1349.

14. Claesson HE, Dahlen SE. Asthma and leukotrienes: Antileukotrienes as novel anti-asthmatic drugs. J Intern Med 1999;245:205-227.

15. Dworski R, Fitzgerald GA, Oates JA et al. Effect of oral prednisone on airways inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994;149:953-959.

16. LaViolette M, Malmstrom K, Lu S et al, for the Montelukast/Beclomethasone Additivity Group. Montelukast added to inhaled beclomethasone in treatment of asthma. Am J Respir Crit Care Med 1999;160:1862-1868.

17. Vaquerizo MJ, Casan P, Castillo J et al, for the CASIOPEA Study Group. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003;58:204-211.

18. Price DB, Hernandez D, Magyar P et al, for the Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy (COMPACT) International. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003;58:211-216.

19. Volovitz B, Dueñas-Meza E, Chmielewska-Szewczyk DA et al. Comparison of oral montelukast and inhaled cromolyn with respect to preference, satisfaction, and adherence: A multicenter, randomized, open-label, crossover study in children with mild to moderate persistent asthma. Curr Ther Res 2000;61(7):490-506.